{"id":"https://openalex.org/W3092820005","doi":"https://doi.org/10.23938/assn.0913","title":"Results of implementation of a pilot antimicrobial stewardship program (ASP) in Primary Care","display_name":"Results of implementation of a pilot antimicrobial stewardship program (ASP) in Primary Care","publication_year":2020,"publication_date":"2020-10-15","ids":{"openalex":"https://openalex.org/W3092820005","doi":"https://doi.org/10.23938/assn.0913","mag":"3092820005","pmid":"https://pubmed.ncbi.nlm.nih.gov/33057243"},"language":"es","primary_location":{"id":"doi:10.23938/assn.0913","doi":"https://doi.org/10.23938/assn.0913","is_oa":true,"landing_page_url":"https://doi.org/10.23938/assn.0913","pdf_url":"https://doi.org/10.23938/assn.0913","source":{"id":"https://openalex.org/S2909877","display_name":"Anales del Sistema Sanitario de Navarra","issn_l":"1137-6627","issn":["1137-6627","2340-3527"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","ddh","doaj","fecyt-seal","jufo-1","latindex","medline","poland-20","russia-white-list-2","scielo"],"host_organization":"https://openalex.org/P4327983467","host_organization_name":"Gobierno de Navarra","host_organization_lineage":["https://openalex.org/P4327983467"],"host_organization_lineage_names":["Gobierno de Navarra"],"type":"journal"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anales del Sistema Sanitario de Navarra","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.23938/assn.0913","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008025853","display_name":"Natalia Alzueta","orcid":"https://orcid.org/0000-0002-8513-239X","observed_orcids":["https://orcid.org/0000-0002-8513-239X"]},"institutions":[{"id":"https://openalex.org/I4210088234","display_name":"Servicio Navarro de Salud","ror":"https://ror.org/005dknr06","country_code":"ES","type":"government","lineage":["https://openalex.org/I4210088234"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"N Alzueta Isturiz","raw_affiliation_strings":["Servicio de Asesor\u00eda e Informaci\u00f3n del Medicamento. Subdirecci\u00f3n de Farmacia. Servicio Navarro de Salud-Osasunbidea. natalia.alzueta.isturiz@navarra.es","BREVES0 Resultados de la implementaci\u00f3n de un programa piloto","DDD siguieron el mismo patr\u00f3n. En ambos grupos de EAP se mantuvo constante el n\u00famero de pacientes tratados con cefalosporinas de tercera generaci\u00f3n, mientras que aumenta-ron de forma similar los tratados con cefalosporinas de pri-mera generaci\u00f3n y con penicilinas sensibles a betalactamasa. En los EAP con PROA aument\u00f3 significativamente menos el n\u00famero de pacientes tratados con fosfomicina-trometamol (4,0 vs 11,5%), reduciendo su consumo en DDD mientras que aumentaron en los EAP","antibi\u00f3ti-cos disminuy\u00f3 significativamente m\u00e1s en el grupo de EAP con PROA (-9,","en Navarra"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Servicio de Asesor\u00eda e Informaci\u00f3n del Medicamento. Subdirecci\u00f3n de Farmacia. Servicio Navarro de Salud-Osasunbidea. natalia.alzueta.isturiz@navarra.es","institution_ids":["https://openalex.org/I4210088234"]},{"raw_affiliation_string":"BREVES0 Resultados de la implementaci\u00f3n de un programa piloto","institution_ids":[]},{"raw_affiliation_string":"DDD siguieron el mismo patr\u00f3n. En ambos grupos de EAP se mantuvo constante el n\u00famero de pacientes tratados con cefalosporinas de tercera generaci\u00f3n, mientras que aumenta-ron de forma similar los tratados con cefalosporinas de pri-mera generaci\u00f3n y con penicilinas sensibles a betalactamasa. En los EAP con PROA aument\u00f3 significativamente menos el n\u00famero de pacientes tratados con fosfomicina-trometamol (4,0 vs 11,5%), reduciendo su consumo en DDD mientras que aumentaron en los EAP","institution_ids":[]},{"raw_affiliation_string":"antibi\u00f3ti-cos disminuy\u00f3 significativamente m\u00e1s en el grupo de EAP con PROA (-9,","institution_ids":[]},{"raw_affiliation_string":"en Navarra","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041513989","display_name":"C Fontela Bulnes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C Fontela Bulnes","raw_affiliation_strings":["vs -1,7%), especialmente en el caso de fluo-roquinolonas (-25 vs -20,4%), macr\u00f3lidos (-20,4 vs -8,5%) y amoxicilina-clavul\u00e1nico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"vs -1,7%), especialmente en el caso de fluo-roquinolonas (-25 vs -20,4%), macr\u00f3lidos (-20,4 vs -8,5%) y amoxicilina-clavul\u00e1nico","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068874374","display_name":"Amaya Echeverr\u00eda Gorriti","orcid":"https://orcid.org/0000-0001-9225-5323","observed_orcids":["https://orcid.org/0000-0001-9225-5323"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Echeverr\u00eda Gorriti","raw_affiliation_strings":["vs -1,7%), especialmente en el caso de fluo-roquinolonas (-25 vs -20,4%), macr\u00f3lidos (-20,4 vs -8,5%) y amoxicilina-clavul\u00e1nico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"vs -1,7%), especialmente en el caso de fluo-roquinolonas (-25 vs -20,4%), macr\u00f3lidos (-20,4 vs -8,5%) y amoxicilina-clavul\u00e1nico","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068708345","display_name":"Alberto Gil-Setas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Gil Setas","raw_affiliation_strings":["vs -1,7%), especialmente en el caso de fluo-roquinolonas (-25 vs -20,4%), macr\u00f3lidos (-20,4 vs -8,5%) y amoxicilina-clavul\u00e1nico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"vs -1,7%), especialmente en el caso de fluo-roquinolonas (-25 vs -20,4%), macr\u00f3lidos (-20,4 vs -8,5%) y amoxicilina-clavul\u00e1nico","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086493279","display_name":"Pablo Aldaz Herce","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P Aldaz Herce","raw_affiliation_strings":["BREVES0 Resultados de la implementaci\u00f3n de un programa piloto","DDD siguieron el mismo patr\u00f3n. En ambos grupos de EAP se mantuvo constante el n\u00famero de pacientes tratados con cefalosporinas de tercera generaci\u00f3n, mientras que aumenta-ron de forma similar los tratados con cefalosporinas de pri-mera generaci\u00f3n y con penicilinas sensibles a betalactamasa. En los EAP con PROA aument\u00f3 significativamente menos el n\u00famero de pacientes tratados con fosfomicina-trometamol (4,0 vs 11,5%), reduciendo su consumo en DDD mientras que aumentaron en los EAP","antibi\u00f3ti-cos disminuy\u00f3 significativamente m\u00e1s en el grupo de EAP con PROA (-9,","en Navarra"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BREVES0 Resultados de la implementaci\u00f3n de un programa piloto","institution_ids":[]},{"raw_affiliation_string":"DDD siguieron el mismo patr\u00f3n. En ambos grupos de EAP se mantuvo constante el n\u00famero de pacientes tratados con cefalosporinas de tercera generaci\u00f3n, mientras que aumenta-ron de forma similar los tratados con cefalosporinas de pri-mera generaci\u00f3n y con penicilinas sensibles a betalactamasa. En los EAP con PROA aument\u00f3 significativamente menos el n\u00famero de pacientes tratados con fosfomicina-trometamol (4,0 vs 11,5%), reduciendo su consumo en DDD mientras que aumentaron en los EAP","institution_ids":[]},{"raw_affiliation_string":"antibi\u00f3ti-cos disminuy\u00f3 significativamente m\u00e1s en el grupo de EAP con PROA (-9,","institution_ids":[]},{"raw_affiliation_string":"en Navarra","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042068297","display_name":"Javier Garj\u00f3n","orcid":"https://orcid.org/0000-0002-0126-7431","observed_orcids":["https://orcid.org/0000-0002-0126-7431"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J Garj\u00f3n Parra","raw_affiliation_strings":["BREVES0 Resultados de la implementaci\u00f3n de un programa piloto","DDD siguieron el mismo patr\u00f3n. En ambos grupos de EAP se mantuvo constante el n\u00famero de pacientes tratados con cefalosporinas de tercera generaci\u00f3n, mientras que aumenta-ron de forma similar los tratados con cefalosporinas de pri-mera generaci\u00f3n y con penicilinas sensibles a betalactamasa. En los EAP con PROA aument\u00f3 significativamente menos el n\u00famero de pacientes tratados con fosfomicina-trometamol (4,0 vs 11,5%), reduciendo su consumo en DDD mientras que aumentaron en los EAP","antibi\u00f3ti-cos disminuy\u00f3 significativamente m\u00e1s en el grupo de EAP con PROA (-9,","en Navarra"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BREVES0 Resultados de la implementaci\u00f3n de un programa piloto","institution_ids":[]},{"raw_affiliation_string":"DDD siguieron el mismo patr\u00f3n. En ambos grupos de EAP se mantuvo constante el n\u00famero de pacientes tratados con cefalosporinas de tercera generaci\u00f3n, mientras que aumenta-ron de forma similar los tratados con cefalosporinas de pri-mera generaci\u00f3n y con penicilinas sensibles a betalactamasa. En los EAP con PROA aument\u00f3 significativamente menos el n\u00famero de pacientes tratados con fosfomicina-trometamol (4,0 vs 11,5%), reduciendo su consumo en DDD mientras que aumentaron en los EAP","institution_ids":[]},{"raw_affiliation_string":"antibi\u00f3ti-cos disminuy\u00f3 significativamente m\u00e1s en el grupo de EAP con PROA (-9,","institution_ids":[]},{"raw_affiliation_string":"en Navarra","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2982,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.59385835,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"43","issue":"3","first_page":"373","last_page":"379"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10897","display_name":"Antibiotic Use and Resistance","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10897","display_name":"Antibiotic Use and Resistance","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11080","display_name":"Surgical site infection prevention","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13555","display_name":"Healthcare cost, quality, practices","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3600","display_name":"General Health Professions"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antimicrobial-stewardship","display_name":"antimicrobial stewardship","score":0.8989999890327454},{"id":"https://openalex.org/keywords/primary-care","display_name":"primary care","score":0.7710000276565552},{"id":"https://openalex.org/keywords/antibiotic-use","display_name":"antibiotic use","score":0.7829999923706055},{"id":"https://openalex.org/keywords/fluoroquinolones","display_name":"fluoroquinolones","score":0.8410000205039978},{"id":"https://openalex.org/keywords/macrolides","display_name":"macrolides","score":0.9760000109672546},{"id":"https://openalex.org/keywords/beta-lactam-antibiotics","display_name":"beta-lactam antibiotics","score":0.8199999928474426},{"id":"https://openalex.org/keywords/cephalosporins","display_name":"cephalosporins","score":0.9610000252723694},{"id":"https://openalex.org/keywords/defined-daily-doses","display_name":"defined daily doses","score":0.9819999933242798},{"id":"https://openalex.org/keywords/program-implementation","display_name":"program implementation","score":0.5519999861717224},{"id":"https://openalex.org/keywords/navarre","display_name":"Navarre","score":0.9190000295639038}],"concepts":[{"id":"https://openalex.org/C2984752397","wikidata":"https://www.wikidata.org/wiki/Q3259956","display_name":"Primary care","level":2,"score":0.6845190525054932},{"id":"https://openalex.org/C2776040555","wikidata":"https://www.wikidata.org/wiki/Q19903321","display_name":"Antimicrobial stewardship","level":4,"score":0.6591821908950806},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5006155967712402},{"id":"https://openalex.org/C163432668","wikidata":"https://www.wikidata.org/wiki/Q623543","display_name":"Primary health care","level":3,"score":0.4372097849845886},{"id":"https://openalex.org/C2777950569","wikidata":"https://www.wikidata.org/wiki/Q17021836","display_name":"Stewardship (theology)","level":3,"score":0.4327021539211273},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.2102070450782776},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.17126843333244324},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.08568271994590759},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.07787570357322693},{"id":"https://openalex.org/C94665300","wikidata":"https://www.wikidata.org/wiki/Q63391344","display_name":"Antibiotic resistance","level":3,"score":0.06073066592216492},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.0},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.0},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C94625758","wikidata":"https://www.wikidata.org/wiki/Q7163","display_name":"Politics","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000073602","descriptor_name":"Antimicrobial Stewardship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011320","descriptor_name":"Primary Health Care","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013030","descriptor_name":"Spain","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.23938/assn.0913","doi":"https://doi.org/10.23938/assn.0913","is_oa":true,"landing_page_url":"https://doi.org/10.23938/assn.0913","pdf_url":"https://doi.org/10.23938/assn.0913","source":{"id":"https://openalex.org/S2909877","display_name":"Anales del Sistema Sanitario de Navarra","issn_l":"1137-6627","issn":["1137-6627","2340-3527"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","ddh","doaj","fecyt-seal","jufo-1","latindex","medline","poland-20","russia-white-list-2","scielo"],"host_organization":"https://openalex.org/P4327983467","host_organization_name":"Gobierno de Navarra","host_organization_lineage":["https://openalex.org/P4327983467"],"host_organization_lineage_names":["Gobierno de Navarra"],"type":"journal"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anales del Sistema Sanitario de Navarra","raw_type":"journal-article"},{"id":"pmid:33057243","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33057243","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anales del sistema sanitario de Navarra","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:4ab4e7f4663f4dbaad96f2c6fa33160a","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/4ab4e7f4663f4dbaad96f2c6fa33160a","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Anales del Sistema Sanitario de Navarra, Vol 43, Iss 3 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.23938/assn.0913","doi":"https://doi.org/10.23938/assn.0913","is_oa":true,"landing_page_url":"https://doi.org/10.23938/assn.0913","pdf_url":"https://doi.org/10.23938/assn.0913","source":{"id":"https://openalex.org/S2909877","display_name":"Anales del Sistema Sanitario de Navarra","issn_l":"1137-6627","issn":["1137-6627","2340-3527"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","ddh","doaj","fecyt-seal","jufo-1","latindex","medline","poland-20","russia-white-list-2","scielo"],"host_organization":"https://openalex.org/P4327983467","host_organization_name":"Gobierno de Navarra","host_organization_lineage":["https://openalex.org/P4327983467"],"host_organization_lineage_names":["Gobierno de Navarra"],"type":"journal"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anales del Sistema Sanitario de Navarra","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3092820005.pdf","grobid_xml":"https://content.openalex.org/works/W3092820005.grobid-xml"},"referenced_works_count":6,"referenced_works":["https://openalex.org/W2043995381","https://openalex.org/W2164115636","https://openalex.org/W2893476743","https://openalex.org/W2899841051","https://openalex.org/W2990781956","https://openalex.org/W3025928092"],"related_works":["https://openalex.org/W3015155873","https://openalex.org/W7161824414","https://openalex.org/W4281779276","https://openalex.org/W2770618463","https://openalex.org/W3016815676","https://openalex.org/W3088930810","https://openalex.org/W3135912168","https://openalex.org/W4380080372","https://openalex.org/W4414591012","https://openalex.org/W4361222077"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,92],"aim":[2],"of":[3,11,45,83,94,137,162],"this":[4],"study":[5,32],"was":[6,167,178],"to":[7],"evaluate":[8],"the":[9,38,127,135],"implementation":[10,53],"a":[12],"pilot":[13],"antimicrobial":[14],"stewardship":[15],"program":[16],"(ASP)":[17],"in":[18,24,43,54,81,102,176,182],"Primary":[19],"Health":[20],"Care":[21],"teams":[22],"(PHCT)":[23],"Navarre":[25],"(Spain).":[26],"MATERIAL":[27],"AND":[28],"METHODS:":[29],"Non-randomized":[30],"experimental":[31],"performed":[33],"with":[34,96,104,110,139,146,158,164],"data":[35,70],"obtained":[36],"from":[37],"electronic":[39],"pharmacy":[40],"records.":[41],"Differences":[42],"consumption":[44,174],"antibiotics":[46,98],"before":[47],"(2018)":[48],"and":[49,73,78,86,119,151],"after":[50],"(2019)":[51],"ASP":[52,63,105,185],"twelve":[55,60],"PHCT":[56,61,103,131,157,183],"were":[57,64],"calculated.":[58],"Another":[59],"without":[62,184],"used":[65],"for":[66],"comparison.":[67],"We":[68],"analysed":[69],"on":[71],"global":[72],"beta-lactams,":[74],"fluoroquinolones,":[75],"macrolides,":[76],"cephalosporines":[77],"fosfomycin-trometamol,":[79],"expressed":[80,175],"number":[82,93,136,161],"treated":[84],"patients":[85,95,138,163],"DDD":[87,125],"(defined":[88],"daily":[89],"doses).":[90],"RESULTS:":[91],"prescribed":[97,140,147,165],"decreased":[99],"significantly":[100],"more":[101],"(-9.1":[106],"vs.":[107,113,117,122,170,187],"-1.7%),":[108],"particularly":[109],"fluoroquinolones":[111],"(-25":[112],"-20.4%),":[114],"macrolids":[115],"(-20.4":[116],"-8.5%)":[118],"amoxicillin-clavulanic":[120],"(-10.3":[121],"-2.5%).":[123],"Decreased":[124],"followed":[126],"same":[128],"pattern.":[129],"Both":[130],"groups":[132],"kept":[133],"constant":[134],"third":[141],"generation":[142,149],"cephalosporins,":[143],"while":[144,172,180],"those":[145],"first":[148],"cephalosporins":[150],"betalactamase-sensible":[152],"penicilins":[153],"increased":[154,160],"similarly.":[155],"In":[156],"ASP,":[159],"phos-phomycin-trometamol":[166],"smaller":[168],"(4.0":[169],"11.5%)":[171],"its":[173],"DDDs":[177],"reduced":[179],"increasing":[181],"(-1":[186],"10%,":[188],"p<0.001).":[189]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-10-22T00:00:00"}